title: Choriocarcinoma and gestational trophoblastic disease.
abstract: Gestational trophoblastic disease (GTD) encompasses a unique group of uncommon but interrelated conditions derived from placental trophoblasts. For the purposes of discussion GTD is the appropriate collective name for hydatidiform mole, whereas the term gestational trophoblastic neoplasia (GTN) is reserved for cases with persistent human chorionic gonadotropin (hCG) titer elevation after evacuation of hydatidiform mole, metastatic disease, or choriocarcinoma. Although the pathology and clinical behavior of CM and PM are different, the initial management of both conditions is surgical evacuation by suction curettage, determination of the baseline, and follow-up with (hCG) titers. There are guidelines for risk-factor scoring and a staging system that classifies untreated patients into distinct prognostic categories so that treatment outcomes can be objectively compared. The rates of GTN and choriocarcinoma are decreasing and survival has dramatically improved.
authors.affiliation: University of New Mexico Health Sciences Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, 2211 Lomas Boulevard NE, Albuquerque, NM 87131-5286, USA. Hsmith@salud.unm.edu
authors.forename: Harriet O
authors.initials: HO
authors.lastname: Smith
authors.forename: Ernest
authors.initials: E
authors.lastname: Kohorn
authors.forename: Laurence A
authors.initials: LA
authors.lastname: Cole
mesh_terms: D006063:Chorionic Gonadotropin / Q000097:blood; D005260:Female; D031901:Gestational Trophoblastic Disease / Q000473:pathology* / Q000628:therapy*; D006801:Humans; D009367:Neoplasm Staging; D011247:Pregnancy; D011256:Pregnancy Outcome; D012307:Risk Factors
chemical_list: D006063:Chorionic Gonadotropin